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Abstract:  
Several studies have demonstrated a link between blood viscosity and various forms of liver dysfunction. Therefore, we 
investigated the effect of liver protective herbal materials, Sesamin combined with extract of Schisandra chinensis berry 
(Schisandra) for its potential to improve blood fluidity in humans. Ten human subjects were recruited to study the effect of 
sesamin combined with schisandra extract (SCH) for two weeks on blood viscosity. Blood fluidity was measured as the transit 
time for 100μl of heparinized whole blood to pass through a micro-channel array setup at baseline, 1 week and 2 weeks. For 
safety assessment, blood biochemistry, hematology and urine analysis were taken at baseline, 1 week and 2 weeks after SCH 
administration. No safety concern and adverse effects were observed during the 2-week continuous intake period. Intake of SCH 
reduced blood passage time by 9.0% and 9.7% at 1 and 2 weeks, respectively. In conclusion, this pilot clinical study indicates 
that the combined administration of sesamin with schisandra extract could improve blood fluidity after 1 week of oral intake and 
this effect was sustained up to 2 weeks.  
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Background: 
There is a common belief in the Southeast Asian Chinese 
community that a smooth blood circulation is important for 
good health. There are several “blood cleansing” Traditional 
Chinese Medicinal (TCM) herbs shown to improve blood 
circulation by reducing blood viscosity and promoting blood 
circulation in animal studies [1, 2]. Blood viscosity or 
fluidity is influenced by circulating plasma lipoproteins [3, 
4], platelet activity and other physiological parameters [5]. 
Modulating these components, possibly by improving 
metabolic function might improve fluidity and blood flow. 
Several studies have demonstrated a link between these 
parameters, blood viscosity and various forms of liver 
dysfunction [6, 7, 8]. In linking traditional health concepts 
with scientific rationale, we hypothesize that liver protective 
‘blood cleansing’ TCM herb materials may help to reduce 
blood viscosity. 
 
Sesamin, a lignan that occurs exclusively in sesame seeds, 
has been reported to inhibit cholesterol absorption and 
synthesis [9], in addition to improving hepatic detoxification 
in rats [10]. Schisandra chinensis with common names like 
Schisandra, Magnolia vine and Wu-wei-zi, similarly, has 
been reported to confer liver protective effect in a rat model 
of hepatotoxicity [11, 12] and is an established Chinese 
herbal medicine associated with liver protection and 
function [13].  In the present study, we examined the action 
of sesamin-schisandra extract combination for its potential 
to improve blood fluidity in humans. 
 
 
 
 
Methodology: 
Subjects 
Healthy subjects who had given written informed consent in 
accordance with the “Declaration of Helsinki” were screened 
for eligibility. Subjects eligible for the study showed “above 
average” blood passage time of ≥ 44.0 sec when tested 
during screening at one week and two weeks prior to Day 0. 
Subjects who failed to meet the criteria were excluded from 
the study. The ‘normal’ blood passage time of ≤ 44 sec is 
derived from the mean value of 51 healthy male volunteers 
in a previous investigation (data not included).  
 
Exclusion criteria included drug allergy, gastrointestinal 
disorder or surgery, respiratory or cardiac disorder, 
excessive intake of tobacco (n50 cigarettes per day), alcohol 
(>equivalent of 120 ml ethyl alcohol), significant irregular 
dietary habits, blood donation within two weeks of study 
initiation and any condition deemed unsuitable for study 
participation. Subjects would be withdrawn from the study 
in the event they need to take medication (such as aspirin, 
anticogulants) that might affect blood viscosity. Of the 20 
subjects initially screened for each group, only ten subjects 
were found to be eligible. 
 
Study design 
Ten healthy male subjects with mean age of 51 years (range 
37 to 69), mean body weight of  75.8 kg  (range 60.5 to 
107.6) and mean BMI of 26.5 (range 21.0 to 37.6), 
participated in the study. In the 2-week, open labelled 
intervention trial with subjects acted as their own controls, 
each volunteer consumed 2 tablets of sesamin-schisandra 
combination (SCH) (Cerebos Pacific Limited, Singapore),  
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twice daily.  Each SCH tablet contains 2.5 mg sesamin, 65 
mg schisandra extract and 3.75 IU Vitamin E. The subjects 
were advised to maintain their regular dietary habits and 
physical activities, and avoid any supplement (such as 
ginkgo leaf extract) or medication (such as aspirin, 
anticogulants) that might affect blood viscosity.  
 
The effect of SCH on blood fluidity was assessed at baseline 
(week 0), 1-week and 2-week after continuous oral intake. 
At each time point, fasting blood samples for blood fluidity 
assessment were taken in the morning before breakfast. 
Blood chemistry, hematology and urine tests for safety 
assessments were performed at screening (2 weeks prior to 
study) and 2 weeks post dosing.  
 
Measurement of blood viscosity or fluidity 
Blood fluidity was assessed using a microchannel array flow 
analyser (MC-FAN) (Hitachi-Haramachi Electronics Co. Ltd) 
as described by Kikuchi (1995) [14]. Blood (5 ml) obtained 
by venpuncture of an antecubital vein was collected in 
vacuum sampler tubes added with 0.25 ml heparin solution 
(1000 units/ml). The transit time for 100 µl of whole blood 
to flow through the 8736-parallel-row micro-channel array 
(channel width 7 µm, length 30 µm, depth 4.5 µm; Bloody 
6-7, Hitachi Haramachi Electronics, Japan) was measured at 
a pressure of 20 cm H2O. The microchannel flow analyser 
was calibrated with the saline before each measurement of 
blood passage time. The transit time was then converted into 
blood passage time to adjust for the transit time of saline. 
The blood passage time is defined as the ratio of “transit 
time for blood (sample) × 12 s” to “transit time for saline”. 
 
Safety assessment 
Haematology, blood biochemistry [total protein, albumin, 
total bilirubin, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyltransferase (γ-GT), 
Alkaline phosphatase (ALP), Lactic dehydrogenase (LDH)], 
total cholesterol, HDL-cholsterol, LDL-cholesterol, 
triglycerides, fasting blood sugar and urine tests were 
performed 2 weeks before and after SCH administration. 
 
Statistical analysis 
Distribution-free non-parametric statistical tests were 
employed.  The Mann Whitney U test was used to compare 
the differences at different time points over 2 weeks. Blood 
transit time is expressed as Mean ± Standard Error of Mean 
(SEM).
 
 
Figure 1: Effect of continuous intake of Schisandra for 2 weeks on the fasting blood passage time. There was a sustained 
decreasing trend in blood passage time during 2 weeks of Schisandra administration. Values represent Mean ± SEM. 
 
Results: 
Among the 10 subjects, 1 subject was found to have 
increased platelet aggregation (blood passing time>70s) after 
1 week of SCH. The data from this particular subject was 
excluded from the study.  
 
Effect of SCH intake 
 Following continuous intake of Schisandra for 2 weeks the 
fasting blood passage time was reduced by 9.0% and 9.7% at 
week 1 and week 2, respectively. The baseline blood 
passage time prior to intake of SCH tablets was 53.5±3.5 sec 
as compared to 47.2±3.2 sec and 47.2±1.7 sec at Week 1 and 
Week 2.  Although this change was not statistically 
significant, there was a sustained decreasing trend in blood 
passage time during 2 weeks of Schisandra administration 
(Figure 1). 
 
Safety parameters 
Haematology, blood biochemistry, and urine tests did not 
show any abnormal change throughout the study period of 
SCH administration. The liver function indicators and 
plasma lipids measured before and after SCH administration 
is shown in Table 1 (see supplementary material). The  
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baseline activities of these enzymes, ALT, AST, ALP and γ-
GT were similar to that at week 2. The baseline pre-study 
plasma levels of total cholesterol, HDL- cholesterol, LDL- 
cholesterol and triglycerides were marginally higher than the 
reference range and 2 weeks of SCH treatment did not cause 
any significant change in lipid parameters.  
 
Discussion:  
In human subjects, the fasting blood passing time shows a 
sustained decreasing trend over the two-week trial period, 
suggesting that SCH may have beneficial effect in 
promoting blood fluidity. The blood passage time following 
SCH intake were similar at week 1 and week 2 when 
compared to baseline (week 0), suggesting that a limit of 
action was reached within that time frame. As shown in 
figure 1, the blood passage time stabilized at 47 sec and did 
not fall below the pre-determined ‘normal’ blood passage 
time (≤ 44 sec), it appears that SCH has a sustained 
beneficial effect on blood fluidity. This ceiling of activity in 
reducing blood viscosity and no undesirable change in 
haematology, liver function indicators, lipid profiles and 
urine tests also infer safety for the consumption of sesamin-
schisandra extract combination.  
 
Various chinese medicinal herbs claim to increase blood 
circulation and combat “blood stasis” in humans [15] (Shen 
and Cui, 1998). Scientific research has substantiated the 
ability of several herbs to reduce blood viscosity, and in the 
case of the popular Ginko biloba, platelet aggregation [15]. 
Herbal combinations with demonstrated clinical effects in 
human subjects include ‘Pushen’ [16] and ‘Dahuang 
Zhechong Wan’ [17]. Another well-known natural remedy is 
garlic (Allium sativum), which exhibits blood viscosity 
reducing quality and is associated with a reduction in 
cholesterol levels, platelet aggregation and overall reduction 
in cardiovascular disease risk [18]. Kiesewetter and 
colleagues  [19]  discussed that improved blood fluidity 
attributed to garlic can increase capillary perfusion which 
can have a cleansing effect, contributing to ‘purification’ of 
the microcirculation.    
 
In contrast to Gingko biloba and garlic, where a reduction in 
platelet aggregation and/or plasma lipids is the proposed 
mechanism for reducing blood viscosity, sesamin in 
combination with schisandra extract might work by an 
indirect route of enhancing liver metabolic functions. A 
recent DNA microarray study indicated that sesamin 
regulates the metabolism of lipids, xenobiotics, and alcohol 
at the mRNA level [20]. Moreover, several studies supported 
the liver protective efficacy of sesamin and schisandra 
extract [10, 12, 13]. In support of our hypothesis, Xie and 
colleagues  [2] showed that a combination of 4 herbs 
including ‘Dang gui’ (Angelica Sinensis) and ‘Dan Shen’ 
(Salviae Miltiorrhizae) could improve blood circulation 
whilst reducing oxidative damage in mice with chronic liver 
damage. Together with the current data, this presents a link 
between liver protection and blood circulation. 
 
Considering this is the first pilot clinical study on the 
combined efficacy and safety of sesamin and schisandra 
extract, and majority of data is derived from animal studies, 
it warrants further investigations to confirm the role of 
sesamin and schisandra extract in improving blood fluidity 
and flow. In conclusion, this study indicates that SCH can 
enhance blood fluidity without causing undesirable side 
effect.  
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Blood Chemistry  Baseline*  Week 2 
Liver function indicator  U/L  U/L 
Aminotransferase (ALT) 44.8±13.0 45.2±13.5 
Aspartate aminotransferase (AST)  31.3±4.4  31.1±6.0 
Alkaline Phosphatase (ALP) 248.4±3.6  252.8±15.6 
Gamma-glutamyltransferase γ-GT 65.7±3.8  63.4±13.6 
Plasma lipid  mg/dL  mg/dL 
Total cholesterol  220.1±8.27  219.0±7.31 
HDL-Cholesterol 52.4±3.69  51.0±2.77 
LDL-Cholesterol 139.7±5.42  139.2±5.11 
Triglycerides 135.4±24.14  138.1±13.63 
Table 1: Blood Chemistry showing results of liver function test and plasma lipid levels in subjects before and after 
administration with SCH. SCH supplementation for 2 weeks did not cause any undesirable change in liver function indicators 
and plasma lipid profiles of the subjects. Values represent Mean ± SEM. 
* Measurements were taken 2 weeks prior to 
commencement of SCH intake.  